טוען...
No clinically significant pharmacokinetic interactions between dolutegravir and daclatasvir in healthy adult subjects
BACKGROUND: Daclatasvir (DCV) is an NS5A replication complex inhibitor recently approved for chronic hepatitis C virus treatment. METHODS: To assess drug interactions between the HIV integrase strand transfer inhibitor dolutegravir (DTG) and DCV, subjects were randomized into 1 of 2 sequences in an...
שמור ב:
| הוצא לאור ב: | BMC Infect Dis |
|---|---|
| Main Authors: | , , , , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
BioMed Central
2016
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4957413/ https://ncbi.nlm.nih.gov/pubmed/27450277 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12879-016-1629-5 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|